I A Lorimer

Summary

Affiliation: Ottawa Regional Cancer Centre
Country: Canada

Publications

  1. ncbi request reprint Activation of extracellular-regulated kinases by normal and mutant EGF receptors
    I A Lorimer
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada
    Biochim Biophys Acta 1538:1-9. 2001
  2. ncbi request reprint Induction of apoptosis in glioblastoma cells by an atypical protein kinase C pseudosubstrate peptide
    Ian A J Lorimer
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, Ontario, Canada
    Anticancer Res 22:623-31. 2002
  3. ncbi request reprint Mutant epidermal growth factor receptors as targets for cancer therapy
    I A J Lorimer
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, 503 Smyth Road, Ottawa, Ontario, Canada, K1H 1C4
    Curr Cancer Drug Targets 2:91-102. 2002
  4. ncbi request reprint Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
    I A Lorimer
    Ottawa Regional Cancer Centre, Cancer Research Group, 501 Smyth Road, Ottawa, Ontario, Canada, K1H 8L6
    J Immunol Methods 237:147-57. 2000
  5. ncbi request reprint Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII
    R C Landry
    Department of Biochemistry Microbiology and Immunology, University of Ottawa, 451 Smyth, Ottawa, K1H 8M5, Canada
    J Mol Biol 308:883-93. 2001
  6. ncbi request reprint Regulation of p27Kip1 by miRNA 221/222 in glioblastoma
    Jana K Gillies
    Ottawa Health Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada
    Cell Cycle 6:2005-9. 2007
  7. ncbi request reprint A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
    Mary J Mackenzie
    Hamilton Regional Cancer Centre, 699 Concession St, Hamilton, ON, Canada L8V 5C2
    Invest New Drugs 23:165-70. 2005
  8. ncbi request reprint Rescue and propagation of fully retargeted oncolytic measles viruses
    Takafumi Nakamura
    Nat Biotechnol 23:209-14. 2005
  9. ncbi request reprint Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells
    Lakshman Gunaratnam
    Department of Cellular and Molecular Medicine and Kidney Research Center, Faculty of Medicine, University of Ottawa, Ontario, Canada
    J Biol Chem 278:44966-74. 2003
  10. ncbi request reprint A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
    Manijeh Daneshmand
    Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 1C4 Canada
    Clin Cancer Res 9:2457-64. 2003

Collaborators

  • S V Evans
  • Takafumi Nakamura
  • L K Seymour
  • Lawrence Panasci
  • Stephen Russell
  • Gerald Batist
  • Doris A E Parolin
  • Maria Tsirigotis
  • Jana K Gillies
  • Mary J Mackenzie
  • Holger W Hirte
  • Sarah Matthews
  • Wilson H Miller
  • Lakshman Gunaratnam
  • Sylvie J Lavictoire
  • Manijeh Daneshmand
  • R C Landry
  • Douglas A Gray
  • R Mitchell Baldwin
  • Matthew Y Tang
  • Rakesh Goel
  • Lynn Douglas
  • Maroun Jean
  • Pierre P Major
  • Goss Glenwood
  • Glenwood Goss
  • John F Kelly
  • Natalie de Paulsen
  • David Stewart
  • Pierre Major
  • Karim Mekhail
  • Melissa Morley
  • Stephen Lee
  • Eijiro Nakamura
  • Aleksandra Franovic
  • Alex C Klimowicz
  • A C Klimowicz
  • S J Lavictoire
  • S Borisova
  • D T Kottachchi

Detail Information

Publications12

  1. ncbi request reprint Activation of extracellular-regulated kinases by normal and mutant EGF receptors
    I A Lorimer
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada
    Biochim Biophys Acta 1538:1-9. 2001
    ..The different mechanisms of ERK activation used by normal and mutant EGF receptors may be important in understanding the potent tumorigenic activity of EGFRvIII...
  2. ncbi request reprint Induction of apoptosis in glioblastoma cells by an atypical protein kinase C pseudosubstrate peptide
    Ian A J Lorimer
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, Ontario, Canada
    Anticancer Res 22:623-31. 2002
    ..We have assessed the cytotoxicity of an inhibitor of atypical protein kinase C on glioblastoma cells expressing EGFRvIII...
  3. ncbi request reprint Mutant epidermal growth factor receptors as targets for cancer therapy
    I A J Lorimer
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, 503 Smyth Road, Ottawa, Ontario, Canada, K1H 1C4
    Curr Cancer Drug Targets 2:91-102. 2002
    ..This review covers our current understanding of the properties of EGFRvIII, and recent developments in the characterization and therapeutic application of EGFRvIII-specific antibodies...
  4. ncbi request reprint Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
    I A Lorimer
    Ottawa Regional Cancer Centre, Cancer Research Group, 501 Smyth Road, Ottawa, Ontario, Canada, K1H 8L6
    J Immunol Methods 237:147-57. 2000
    ..Thus we were able to redirect retrovirus binding to this tumour-specific target without perturbing the normal function of the ecotropic envelope glycoprotein, but this was not sufficient to mediate infectivity via this receptor...
  5. ncbi request reprint Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII
    R C Landry
    Department of Biochemistry Microbiology and Immunology, University of Ottawa, 451 Smyth, Ottawa, K1H 8M5, Canada
    J Mol Biol 308:883-93. 2001
    ....
  6. ncbi request reprint Regulation of p27Kip1 by miRNA 221/222 in glioblastoma
    Jana K Gillies
    Ottawa Health Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Canada
    Cell Cycle 6:2005-9. 2007
    ..These data show that p27(Kip1) is a direct target for microRNAs 221 and 222, and suggest a role for these microRNAs in promoting the aggressive growth of human glioblastoma...
  7. ncbi request reprint A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
    Mary J Mackenzie
    Hamilton Regional Cancer Centre, 699 Concession St, Hamilton, ON, Canada L8V 5C2
    Invest New Drugs 23:165-70. 2005
    ....
  8. ncbi request reprint Rescue and propagation of fully retargeted oncolytic measles viruses
    Takafumi Nakamura
    Nat Biotechnol 23:209-14. 2005
    ..These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses...
  9. ncbi request reprint Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells
    Lakshman Gunaratnam
    Department of Cellular and Molecular Medicine and Kidney Research Center, Faculty of Medicine, University of Ottawa, Ontario, Canada
    J Biol Chem 278:44966-74. 2003
    ..Moreover, our results suggest that HIF might be involved in oncogenesis to a much higher extent than previously appreciated...
  10. ncbi request reprint A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
    Manijeh Daneshmand
    Ottawa Regional Cancer Centre, Ottawa, Ontario, K1H 1C4 Canada
    Clin Cancer Res 9:2457-64. 2003
    ..Immunohistochemistry for EGFR, activated EGFR, phosphorylated Akt, phosphorylated ERK, p27(Kip1), and beta-catenin was also performed...
  11. ncbi request reprint Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII
    Sylvie J Lavictoire
    Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, Ottawa, Ontario K1H 1C4, Canada
    J Biol Chem 278:5292-9. 2003
    ..These studies show that nascent EGFRvIII in the endoplasmic reticulum associates with Hsp90 and Cdc37, and that the Hsp90 association is necessary to maintain expression of EGFRvIII...
  12. pmc Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity
    Maria Tsirigotis
    Centre for Cancer Therapeutics, Ottawa Health Research Institute, Ottawa, Ontario, Canada
    PLoS ONE 3:e2130. 2008
    ..The signaling pathways that may modulate the pathogenesis of diseases induced by expanded polyglutamine proteins are not well understood...